

CORRESPONDENCE

Open Access



Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis

Yizhao Xie^{1,2†}, Biyun Wang^{1,2†}, Yannan Zhao^{1,2}, Zhonghua Tao^{1,2}, Ye Wang^{1,2}, Guangliang Chen^{2,3*} and Xichun Hu^{1,2*}

Abstract

Ferroptosis, a novel non-apoptotic form of cell death, can induce tumor cell death and treatment resistance. Lipid metabolism is closely related to ferroptosis; however, the effect of mammary adipocytes on breast cancer ferroptosis remains to be elucidated. Here, we established the co-culture system of adipocyte-breast cancer cells and revealed the protection of triple-negative breast cancer from ferroptosis by adipocytes. Then, we performed the lipidomics analysis comparing lipid metabolites of co-cultured and normal-cultured cells. Mechanistically, oleic acid secreted from adipocytes inhibited lipid peroxidation and ferroptosis of triple-negative breast cancer cells in the presence of ACSL3. Taken together, mammary adipocytes can protect breast cancer cells from ferroptosis through oleic acid in the presence of ACSL3. These findings could provide new ideas and targets for tumor treatment.

Keywords: Breast cancer, Adipocytes, Ferroptosis, Cell death, Lipid metabolism

To the editor

Breast cancer cells survive in mammary adipocytes, which provides a unique micro-environment for neoplasia cells. A remodeling effect of adipocytes on breast cancer lipid metabolism was observed and free fatty acids (FFA) and lipid droplets could make breast cancer cells more invasive [1, 2]. Ferroptosis is a non-apoptotic form of cell death driven by excessive lipid peroxidation, which was involved in the pathogenesis, development as well as therapeutic targets of multiple types of cancer including triple-negative breast cancer (TNBC) [3, 4]. Studies found that polyunsaturated fatty acids (PUFAs) could induce peroxidation of lipid bilayer while exogenous

monounsaturated fatty acids (MUFAs) could inhibit ferroptosis [5, 6]. However, the effect of mammary adipocytes on TNBC ferroptosis remains unknown.

We first established the mammary adipocyte-breast cancer cell co-culture system. Mature adipocytes were derived and separated from patients underwent breast cancer surgery and an isolated co-culture system was established using transwell culture dish where adipocyte was in upper level and breast cancer cell was in lower level (Additional file 1: Fig. S1). After 72 h co-culture, red oil staining and Nile red staining were performed showing more lipid droplets in co-culture group than in regular culture group (Additional file 1: Fig. S1). Then, we choose sulfasalazine as ferroptosis inducer and BODIPY[™] 581/591C11 staining as detection of level of lipid peroxidation according to previous data [7–9]. We found that both in TNBC cell lines BT-549 and MDA-MB-231, increased lipid-ROS levels derived from ferroptosis could be induced by Sulfasalazine (SAS), and co-cultured cells significantly inhibited lipid peroxidation detected by flow cytometry compared to normal-cultured cells and was partly rescued by concurrent

[†]Yizhao Xie, Biyun Wang, Guangliang Chen and Xichun Hu have contributed equally to this work.

*Correspondence: guangliang_chen@fudan.edu.cn; huxichun2017@163.com

¹ Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, 270, Dong'an Road, Xuhui District, Shanghai 200032, China


² Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China


Full list of author information is available at the end of the article



administration of ferroptosis inhibitor, ferrostatin-1 (Fig. 1A–C). Transmission electron microscope (TEM) assay also found a marked increased mitochondrial peroxidation of normal-cultured cells compared to co-cultured cells after treatment of SAS (Fig. 1D, Additional file 2: Fig. S2). Moreover, results showed a significantly lower inhibition rate as well as a significantly higher

clone numbers of co-cultured cells compared to normal-cultured cells after treatment of SAS and the growth inhibition could also be partially restored by ferrostatin-1 (Fig. 1E–G). We also introduced apoptosis inhibitor Z-VAD-FMK and autophagy inhibitor 3-MA and found they cannot restore the cell viability of SAS treated cells compared to ferrostatin-1 (Additional file 2: Fig. S2). We





used another type of ferroptosis inducer RSL3 to confirm our results (Additional file 2: Fig. S2). These findings suggest an inhibitory effect of adipocytes on ferroptosis of breast cancer cells.

In order to investigate the mechanisms by which adipocytes inhibit ferroptosis, we firstly conducted a lipidomic analysis on co-cultured and normal-cultured MDA-MB-231 cell lines. Univariate analysis indicated 88 upregulated metabolites and 12 downregulated metabolites in co-cultured cells. The detailed results and expression levels were shown in Additional file 3: Fig. S3 and Tables S1, S2. In brief, the lipidomic analysis suggested a great elevation of phospholipid biosynthesis pathway of co-cultured cells compared to normal-cultured cells. These findings further suggest us adipocytes inhibit ferroptosis through metabolites related to phospholipid biosynthesis with regards to the vital role of acid-containing phospholipids in ferroptosis. We next found a significant higher non-esterified fatty acids (NEFA) levels in co-cultured cell lines compared to normal-cultured cell lines (Additional file 4: Fig. S4). After introduction of exogenous glycerol, oleic acid (MUFA) and stearic acid (PUFA), a significant inhibition of lipid-ROS levels in exogenous oleic acid group compared to control group was observed (Fig. 2A, B). Cell viability tests and clonal formation showed similar results (Additional file 4: Fig. S4). Previous study suggested that exogenous MUFA could decrease the sensitivity of plasma membrane lipids to lethal oxidation in an acyl-CoA synthetase long-chain family member 3 (ACSL3)-dependent manner among fibrosarcoma cells as well as melanoma cells [5]. Thus, we performed ACSL3-knockdown cell lines using shRNA and found that the lipid-ROS levels of sh-ACSL3 showed a reverse of protection against ferroptosis in adipocyte co-cultured group and exogenous MUFA group, with regards to BT-549 and MDA-MB-231 cell lines (Fig. 2C–E). Furthermore, cell viability tests and clonal formation showed similar results considering shACSL3 cell lines (Additional file 5: Fig. S5). Last but not least, for in vivo study, we inoculated MDA-MB-231 cells into fat pad (FP) of left groin and right back subcutaneously (SC) of nude mice, as the schematic diagram showed (Fig. 2F). Then, the mice were treated with SAS. Mouse weight was monitored and no significant difference was observed in treatment groups and control group throughout the dosing period, indicating a good tolerance (Fig. 2G). Consistent with our in vitro outcomes, the ferroptosis inducer SAS significantly reduced tumor growth in SC group instead of FP group, indicating a protection of adipocytes against ferroptosis (Fig. 2H). Moreover, we found increased lipids in FP tumor using oil-red staining, increased mitochondrial injury in SC tumor using TEM and decreased glutathione peroxidase 4 (GPX4) and

solute carrier family 7 member 11 (SLC7A11) levels in SC tumor, which further demonstrated our points (Additional file 6: Fig. S6). Interestingly, previous study found that lymph nodes could protect melanoma cells from ferroptosis by production of MUFA, thus increasing tumor metastasis, which to some extent was conformed to our findings [10]. As more and more clinical trials have been carried out with regards to ferroptosis inducers among cancer patients, our findings could provide valuable information for the benefit of patients.

In conclusion, the present study reveals the protection of adipocytes against breast cancer ferroptosis through MUFA production requiring ACSL3. We also give map to lipidomics of adipocytes co-cultured cells. These findings could provide new ideas and targets for tumor treatment.

Abbreviations

TNBC: Triple-negative breast cancer; MBC: Metastatic breast cancer; HER2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; PR: Progesterone receptor; FFA: Free fatty acids; GPX4: System XC-L-Glutathione reduced-glutathione peroxidase 4; ACSL3: Acyl-CoA synthetase long-chain family member 3; ACSL4: Acyl-CoA synthetase long-chain family member 4; MUFA: Exogeneous monounsaturated fatty acids; TEM: Transmission electron microscope; SAS: Sulfasalazine; PCA: Principal component analysis; DPLA-DS: Orthogonal partial least-squares discrimination analysis; NEFA: Non-esterified fatty acids; FP: Fat pad; SC: Subcutaneous; PUFA-PL: Polyunsaturated fatty acid-containing phospholipids; GPX4: Glutathione peroxidase 4; SLC7A11: Solute carrier family 7 member 11.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13045-022-01297-1>.

Additional file 1 Fig. S1. Adipocyte–breast cancer cell co-culture system. **A** Schematic diagram of co-culture system. **B** Oil Red staining of co-culture group and regular culture group. **C** Nile red staining of co-culture group and regular culture group

Additional file 2 Fig. S2. **A** Cell viability in control or co-cultured MDA-MB-231 cells treated with SAS, SAS+Ferrostatin-1, and in control cells treated with SAS+Z-VAD-FMK or SAS+3-MA. **B** Cell viability in control or co-cultured MDA-MB-231 cells treated with RSL3 or RSL3+ Ferrostatin-1. **C** Supporting TEM images of co-culture and control cells treated with SAS.

Additional file 3 Fig. S3. **A** Lipidomic analysis on co-cultured and normal-cultured MDA-MB-231 cell lines. **B** Volcano plot of univariate statistics. **C** Venn plot of differential metabolites. **D** Boxplot of top 9 differential metabolites ordered by P value. **E** Bubble plot of pathway analysis using SMPDB database. **F** Bar plot of pathway analysis by the HSA set in KEGG.

Additional file 4 Fig. S4. **A** NEFA levels in culture supernatants from control and co-culture MDA-MB-231 and BT-549 cells. **B** Cell viability in MDA-MB-231 and BT-549 cells co-cultured with indicated fatty metabolites or DMSO, then treated with SAS. **C** Representative images of clonogenic assay in MDA-MB-231 and BT-549 cells co-cultured with indicated fatty metabolites and treated with DMSO, SAS or SAS + Ferrostatin-1.

Additional file 5 Fig. S5. **A** Cell viability in shACSL3 and shNC MDA-MB-231 and BT-549 cells co-cultured with adipocytes or OA and then treated with SAS. **B** Representative images of clonogenic assay in shACSL3 and shNC cells co-cultured with adipocytes or OA and treated with DMSO, SAS or SAS + Ferrostatin-1.

Additional file 6 Fig. S6. Supporting figures of mice tumor tissue. **A** Protein levels of GPX4 and SLC7A11 were analyzed by western blotting in tumor of SC and FP group treated with SAS. **B** Adipose infiltration levels tested by Oil Red staining as well as TEM of resected tumor in FP and SC group treated with SAS.

Additional file 7 Table S1. Expression levels of different metabolites.

Additional file 8 Table S2. Pathway enrichments of elevated metabolites.

Additional file 9 Material and Methods.

Acknowledgements

The authors would like to thank Yizhou Jiang and Ding Ma for their kind help in adipocytes separation and thank lab assistants, teachers and colleges for support of this study

Author contributions

YX and BW carried out the experiments and finished the article. YZ, ZT and YW took part in the lab works and database analysis. GC and XH designed and instructed the whole project. All authors read and approved the final manuscript.

Funding

No financial support.

Availability of data and materials

The datasets collected and/or analyzed during this study are not publicly available due to hospital policies but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors approved article for publication.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, 270, Dong'an Road, Xuhui District, Shanghai 200032, China. ²Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. ³Department of Lymphoma, Fudan University Shanghai Cancer Center, 270, Dong'an Road, Xuhui District, Shanghai 200032, China.

Received: 9 March 2022 Accepted: 22 May 2022

Published online: 03 June 2022

References

1. Wang YY, et al. Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. *JCI Insight*. 2017. <https://doi.org/10.1172/jci.insight.87489>.
2. Choi J, Cha YJ, Koo JS. Adipocyte biology in breast cancer: From silent bystander to active facilitator. *Prog Lipid Res*. 2018;69:11–20.
3. Chen X, et al. Broadening horizons: the role of ferroptosis in cancer. *Nat Rev Clin Oncol*. 2021;18(5):280–96.
4. Yu M, et al. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. *Cancer Sci*. 2019;110(10):3173–82.
5. Magtanong L, et al. Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State. *Cell Chem Biol*. 2019;26(3):420–432.e9.
6. Doll S, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. *Nat Chem Biol*. 2017;13(1):91–8.

7. Stockwell BR, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. *Cell*. 2017;171(2):273–85.
8. Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. *Cell*. 2014;156(1–2):317–31.
9. Gout PW, et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. *Leukemia*. 2001;15(10):1633–40.
10. Ubellacker JM, et al. Lymph protects metastasizing melanoma cells from ferroptosis. *Nature*. 2020;585(7823):113–8.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

